Gefitinib Gefticip 250mg Tablet

Name: Gefitinib Gefticip 250mg Tablet
Brand: Welox Pharma Private Limited
Price: 2650 INR
Availability: InStock

Price 2650 INR/ Box

Get a Price/Quote

MOQ : 100 Boxes

Gefitinib Gefticip 250mg Tablet Specification

Life Span
Check package for expiry

Origin of Medicine
India

Salt Composition
Gefitinib 250mg

Packaging Type
Box

Indication
Non-small cell lung cancer (NSCLC)

Dosage Form
Tablet

Pacakaging (Quantity Per Box)
10 tablets per box

Drug Type
Allopathic

Ingredients
Gefitinib

Physical Form
Tablet

Function
Cancer treatment (EGFR inhibitor)

Recommended For
Adults with non-small cell lung cancer

Dosage
250 mg once daily or as directed by physician

Dosage Guidelines
As directed by physician

Suitable For
Adults

Quantity
1*10 Tablets

Storage Instructions
Store below 30C, protected from moisture

Administration Route
Oral

Box Color
White and gray

International Availability
Canada, EU, UK, USA, Australia

Gefitinib Gefticip 250mg Tablet Trade Information

Minimum Order Quantity
100 Boxes

Supply Ability
5000 Boxes Per Month

Delivery Time
7 Days

Gefitinib Gefticip 250mg Tablet About

Unlock a world of gilt-edged cancer care with the acclaimed Gefitinib Gefticip 250mg Tablet, now available internationally-including Canada, EU, UK, USA, and Australia. This ravishing, oral EGFR inhibitor is recommended for adults with non-small cell lung cancer, offering breathtaking support in targeted cancer treatment. Each box contains 10 white and gray tablets, each expertly formulated with 250mg Gefitinib. Simply add to cart and experience the medical excellence originating from India. Store below 30C and use strictly as advised by your physician.

Versatile Application and Distinct Features

Gefitinib Gefticip 250mg Tablet is administered orally, targeting non-small cell lung cancer right at its origin. Its usage is strictly for adults, providing a customized, physician-directed approach to treatment. The medication boasts shelf stability when kept below 30C and away from moisture. The practical packaging of 10 tablets per box makes dosage management effortless for ongoing therapy while its allopathic, scientifically-proven formulation ensures consistent, reliable results.

Reliable Global Supply and Authentic Certification

Gefitinib Gefticip 250mg Tablet is readily dispatched worldwide, including high-demand markets such as the USA, UK, Canada, EU, and Australia. Distinct from generic alternatives, its market value aligns with international healthcare standards, with an asking price reflecting both quality and reliability. Authentic certifications verify its origin and compliance, offering assurance to both patients and medical professionals. Sample policies are transparent, making initial acquisition smooth for bulk buyers and healthcare suppliers.

FAQ's of Gefitinib Gefticip 250mg Tablet:

Q: How should Gefitinib Gefticip 250mg Tablet be administered?

A: Gefitinib Gefticip 250mg Tablet should be taken orally, once daily, or as directed by your physician. Always follow your healthcare professional's specific instructions for optimal results.

Q: What conditions is this medication recommended for?

A: This medication is primarily indicated for adults diagnosed with non-small cell lung cancer (NSCLC) and is part of targeted therapy as an EGFR inhibitor.

Q: When is the best time to take Gefitinib Gefticip 250mg Tablet?

A: The tablet should be taken at the same time every day, as recommended by your physician, to maintain consistent drug levels in your body.

Q: Where is Gefitinib Gefticip 250mg Tablet manufactured and available?

A: The product is manufactured in India and is available in Canada, the European Union, United Kingdom, United States, and Australia.

Q: What are the storage instructions for Gefitinib Gefticip 250mg Tablet?

A: Store the tablets below 30C, in a dry place protected from moisture, and always check the packaging for expiry information.

Q: What are the key benefits of using Gefitinib Gefticip 250mg Tablet?

A: Gefitinib Gefticip offers targeted cancer treatment for NSCLC, potentially improves outcomes, and is supported by a proven safety and efficacy profile in adult patients.

Tell us about your requirement